Föreläsningar och seminarier What is life? lecture: A Discussion of Two AI-Driven Healthcare Paradigm Changes and their Integration: Data-Driven Individual Health and Information-Based Peptide Drugs

Abstract: Contemporary healthcare is focused primarily on identifying and treating clinically defined diseases.  About 10 years ago, we initiated the first efforts on personalized data-driven health for 108 individuals.  Data-driven health included the individual analyses of one’s complete genome and a longitudinal analyses of one’s changing phenotype through phenomic measurements such as the quantification of blood analytes, the gut microbiome and a digital health device for physiological assessments. The success of this effort led to the creation of a wellness company, Arivale, which over a period of 4 years analyzed the genomes and phenomes of 5000 individuals.  These data led to more than 25 different peer-reviewed articles, each giving a different glimpse of the results of scientific (quantitative) wellness.  My lecture will summarize these results, and tell you where we are currently taking data-driven health with the non-profit, Phenome Health.  Data-driven health is delivering “actionable possibilities” for patients (which if individually executed lead to improved wellness or the avoidance of disease), possible disease- or wellness-relevant biomarkers and drug targets, new causal insights into human biology and an extension of the Human Genome Project, which I have termed the Human Phenome Initiative.  I will also discuss a new peptide drug company, P4Bios.  This company will generate peptide drugs that will be capable of interacting with virtually any of the body's information molecules (e.g. proteins, micro-proteins, or any of the different types of RNA).  This approach offers drugs with tremendous scale, range, effectiveness, rapid-discovery cycle, ideal optimization and strikingly low costs.  The integration of the drug targets for wellness, healthy aging, disease prevention as well as disease treatment employing the drug targets that Phenome Health has identified,  P4Bios employ the most  effective tools of AI—knowledge graphs, digital twins and large language models to lead to effective drug discovery and validation via the transcription profiles of millions of individual drugs.  Thus I will discuss 3 different paradigm changes for healthcare:  the Human Genome Program, the Human Phenome Initiative and intrinsically disordered peptide drugs—a revolution in how drug discovery and validation will operate in the future.  

 Biography: Dr. Hood received an MD from Johns Hopkins Medical School and a PhD from Caltech. He was a professor at Caltech for 22 years; a co-founder and chairman of the first cross-disciplinary biology department at the University of Washington for 8 years; a co-founder and president of the Institute for Systems Biology for 18 years—the first organization promoting systems biology. He is in three US National Academies: Science, Medicine and Engineering—one of only 20/more than 6000 to be so honored. He developed the automated DNA sequencer that made the human genome sequence possible and 5 other instruments that laid the technical foundations of modern biology. He is pioneering data-driven and systems-driven 21st century medicine—which will transform healthcare. He has co-founded 17 biotech companies. He has 18 honorary degrees from leading institutions all over the world. He has won a variety of prizes including the Kyoto Prize for technology development, the Lasker Prize for molecular immunology and the National Medal of Science awarded by Obama. He is currently on the faculty of the Institute for Systems Biology and CEO of Phenome Health, a non-profit organization driving the emergence of precision population health. He has written the popular science book “The Age of Scientific Wellness”

https://phenomehealth.org/team/lee-hood-md-phd

Recent Publications

Predictive, preventive, personalized and participatory medicine: back to the future.

Auffray C, Charron D, Hood L.Genome Med. 2010 Aug 26;2(8):57.

A systems approach to clinical oncology uses deep phenotyping to deliver personalized care. Yurkovich JT, Tian Q, Price ND, Hood L.Nat Rev Clin Oncol. 2020 Mar;17(3):183-194. doi: 10.1038/s41571-019-0273-6. Epub 2019 Oct 16.

Personalized, Precision, and N-of-One Medicine: A Clarification of Terminology and Concepts. Huang S, Hood L.Perspect Biol Med. 2019;62(4):617-639. doi: 10.1353/pbm.2019.0036.

Su Y, ..Hood L, Gottardo R, Greenberg PD, Davis MM, Goldman JD, Heath JR.Multiple early factors anticipate post-acute COVID-19 sequelae.Cell. 2022 Mar 3;185(5):881-895

Yurkovich JT, Evans SJ, Rappaport N, Boore JL, Lovejoy JC, Price ND, Hood LE.The transition from genomics to phenomics in personalized population health. Nat Rev Genet. 2024 Apr;25(4):286-302. doi: 10.1038/s41576-023-00674-x. Epub 2023 Dec 13.PMID: 38093095 

Emmert-Streib F, Parkkila S, Laubenbacher R, Mannermaa A, Hood L, Yli-Harja O.The role of digital twins in P4 medicine: A paradigm for modern healthcare. NPJ Digit Med. 2025 Dec 1;8(1):735. doi: 10.1038/s41746-025-02115-x.PMID: 41326644  

Funk CC, Paterson T, Bangs A, Cannon DM, Savage G, Ringger E, Hood L.J Mining the gaps: Deciphering Alzheimer's biology through AI-driven reconciliation.Prev Alzheimers Dis. 2025 Dec 1:100402. doi: 10.1016/j.tjpad.2025.100402. Online ahead of print.PMID: 41326299 

Rappaport N, Nogal B, Perrott K, Domina V, Hood L, Price ND.Annu Early Detection of Wellness-to-Disease Transitions in the AI Era: Implications for Pharmacology and Toxicology. Rev Pharmacol Toxicol. 2025 Sep 25. doi: 10.1146/annurev-pharmtox-062124-013423.

Mardinoglu A, Turkez H, Shong M, Srinivasulu VP, Nielsen J, Palsson BO, Hood L, Uhlen M.Longitudinal big biological data in the AI era. Mol Syst Biol. 2025 Sep;21(9):1147-1165. doi: 10.1038/s44320-025-00134-0. Epub 2025 Aug 5.PMID: 40764831